No 01 2015

Norwegian microbiome diagnostics company Genetic Analysis has placed its GA-map Dysbiosis Test at the Centre for Digestive Diseases (CDD) in Sydney – the company's first placement in Australia and a new milestone in its international expansion.

Nykode Therapeutics has been granted a new US patent covering its individualized neoantigen cancer vaccine VB10.NEO and related modular vaccine designs, strengthening the company's intellectual property position as the neoantigen vaccine field gains momentum.

Bavarian Nordic has upgraded its financial guidance for 2026, now expecting total revenue of approximately DKK 5,700 million and an EBITDA margin of around 30 percent, on the back of continued strength in its Public Preparedness business. The Danish vaccine maker is also launching a new share buyback programme of up to DKK 750 million.

Elicera Therapeutics has reported continued strong results from its Phase I/IIa CARMA study of ELC-301 in relapsed or refractory B-cell lymphoma, with an overall response rate of 91 percent and disease control in all evaluable patients.

The company has announced confidential submission of draft registration statement to the SEC to allow for a potential listing of ADSs in the United States.

The FDA has granted Premarket Approval (PMA) for RefluxStop, the company’s implant-based treatment for gastroesophageal reflux disease (GERD).

Swedish biotech company Akiram Therapeutics has signed an agreement with ITM Isotope Technologies Munich to supply non-carrier-added lutetium-177 for the clinical development of AKIR001.